Swiss maker of X-ray inspection tubes and RF power/plasma-control systems for semiconductor fabs and industrial imaging.
Swiss maker of X-ray inspection tubes and RF power/plasma-control systems for semiconductor fabs and industrial imaging.
Sells components that stay inside customers' machines, chiefly RF generators and matching networks that power chip-making plasma etch and deposition tools, so orders follow the equipment makers' build plans and a few large customers dominate that unit. The X-ray tubes and Yxlon inspection systems follow a different, industrial cycle.
In one line: A niche Swiss Advanced Energy for RF power.
Moat: narrow (IP / patents, customer qualification, process know-how). Qualified components inside semiconductor tools; switching mid-tool-generation is costly.
Headquarters: Flamatt, Switzerland · Founded: 1948 · Employees: 1,832
Size COMET (COTN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $2.78B, the 80th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 301.40 on 18 Nov 2026.
Performance Over six months the shares fell 14.7%, against -0.3% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 2.8% over the last twelve months (peer median +6.3%); the operating margin is 6.5% (peer median 8.3%).
Valuation It trades at 32.8× forward earnings against a peer median of 24.4× (6th most expensive of 18).
Capital Return on invested capital runs 0.7 points below its cost of capital (7.9% WACC).
Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 470M | CHF 457M | CHF 445M | CHF 397M | CHF 586M |
| Revenue growth | — | +3% | +12% | -32% | — |
| Gross profit | CHF 186M | CHF 174M | CHF 191M | CHF 163M | CHF 262M |
| EBITDA | CHF 52.0M | CHF 39.5M | CHF 51.3M | CHF 37.2M | CHF 114M |
| Net income | CHF 17.8M | CHF 12.2M | CHF 32.8M | CHF 15.4M | CHF 78.1M |
| Free cash flow | -CHF 14.4M | CHF 6.78M | CHF 40.1M | -CHF 2.85M | CHF 42.5M |
| Capital expenditure | CHF 59.8M | CHF 42.6M | CHF 12.8M | CHF 27.0M | CHF 23.2M |
| Total debt | n/a | CHF 91.3M | CHF 97.6M | CHF 95.5M | CHF 97.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| COMET COTN.SW | $2.78B | -15% | -3% | 6% | 32.8× | n/a |
| Advanced Energy Industries AEIS | $8.72B | -31% | +32% | 17% | 12.7× | 19.9% |
| MKS MKSI | $14.2B | -32% | +25% | 19% | 10.9× | 21.8% |
| Varex Imaging VREX | $771M | +79% | +5% | 8% | 19.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COTN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.3% | -2.2% | 4th lowest of 21 |
| 6-month return | -14.7% | -0.3% | 6th lowest of 21 |
| Distance from 52-week high | -33.4% | -28.0% | 9th lowest of 21 |
| Revenue growth (TTM) | -2.8% | +6.3% | 2nd lowest of 20 |
| Operating margin | 6.5% | 8.3% | 9th lowest of 20 |
| Forward P/E | 32.8× | 24.4× | 6th most expensive of 18 |
| ROIC minus cost of capital | -0.7 pp | -0.8 pp | 10th highest of 19 |
| EV / EBITDA | 45.4× | 20.9× | 3rd most expensive of 9 |
| Net debt / EBITDA | 0.4× | 2.4× | 2nd least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| Celcuity CELC | United States | $2.73B | -60% | n/a | n/a | n/a | n/a | n/a |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% | +8.0% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 15.7× | 4.7% | +6.8% |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 24.0× | n/a | n/a |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |